Transcriptome profiling reveals that the SM22α-regulated molecular pathways contribute to vascular pathology

Journal of Molecular and Cellular Cardiology

Volumn 72, Issue , 2014, Pages 263-272

  Chen, Rong ^a   Zhang, Fan ^a   Song, Li ^a,b   Shu, Yanan ^a   Lin, Yanling ^a   Dong, Lihua ^a   Nie, Xi ^a   Zhang, Dandan ^a   Chen, Peng ^a   Han, Mei ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Atherosclerosis; NF B; SM22 ; Transcriptome profiling; Vascular inflammation

Indexed keywords

APOLIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RETINOID X RECEPTOR ALPHA; RNA; TRANSGELIN; TUMOR NECROSIS FACTOR ALPHA; ACTIN BINDING PROTEIN; APOLIPOPROTEIN C1; MUSCLE PROTEIN; TAGLN PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HEMATOPOIESIS; HYPERPLASIA; IN VITRO STUDY; INFLAMMATION; LIPID METABOLISM; MALE; MOUSE; NEOINTIMAL HYPERPLASIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RNA SEQUENCE; SM22 ALPHA GENE; TRANSCRIPTOMICS; UPREGULATION; ANIMAL; AORTA; DEFICIENCY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOINTIMA; PATHOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; APOLIPOPROTEIN C-I; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIESIS; INFLAMMATION; LIPID METABOLISM; MALE; MICE; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901309985     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.04.003     Document Type: Article

References (66)

1. Alexander R.W. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995, 25:155-161.
2. Gomez D., Owens G.K. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 2012, 95:156-164.
3. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
4. Gabbiani G., Schmid E., Winter S., Chaponnier C., de Ckhastonay C., Vandekerckhove J., et al. Vascular smooth muscle cells differ from other smooth muscle cells: predominance of vimentin filaments and a specific alpha-type actin. Proc Natl Acad Sci U S A 1981, 78:298-302.
5. Duband J.L., Gimona M., Scatena M., Sartore S., Small J.V. Calponin and SM 22 as differentiation markers of smooth muscle: spatiotemporal distribution during avian embryonic development. Differentiation 1993, 55:1-11.
6. Miano J.M., Cserjesi P., Ligon K.L., Periasamy M., Olson E.N. Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. Circ Res 1994, 75:803-812.
7. van der Loop F.T., Schaart G., Timmer E.D., Ramaekers F.C., van Eys G.J. Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J Cell Biol 1996, 134:401-411.
8. Papke C.L., Cao J., Kwartler C.S., Villamizar C., Byanova K.L., Lim S.M., et al. Smooth muscle hyperplasia due to loss of smooth muscle alpha-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of platelet-derived growth factor receptor-beta. Hum Mol Genet 2013, 22:3123-3137.
9. Castro M.M., Cena J., Cho W.J., Walsh M.P., Schulz R. Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. Arterioscler Thromb Vasc Biol 2012, 32:662-668.
10. Nagai R., Kuro-o M., Aikawa M., Watanabe M., Suzuki T., Yazaki Y. Smooth muscle myosin heavy chain expression in the arterial wall; a new viewpoint for vascular pathology. Rinsho Byori 1995, 43:337-341.
11. Rensen S.S., Niessen P.M., van Deursen J.M., Janssen B.J., Heijman E., Hermeling E., et al. Smoothelin-B deficiency results in reduced arterial contractility, hypertension, and cardiac hypertrophy in mice. Circulation 2008, 118:828-836.
12. Wamhoff B.R., Hoofnagle M.H., Burns A., Sinha S., McDonald O.G., Owens G.K. A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res 2004, 95:981-988.
13. Lenk G.M., Tromp G., Weinsheimer S., Gatalica Z., Berguer R., Kuivaniemi H. Whole genome expression profiling reveals a significant role for immune function in human abdominal aortic aneurysms. BMC Genomics 2007, 8:237.
14. Puig O., Wang I.M., Cheng P., Zhou P., Roy S., Cully D., et al. Transcriptome profiling and network analysis of genetically hypertensive mice identifies potential pharmacological targets of hypertension. Physiol Genomics 2010, 42A:24-32.
15. Shields J.M., Rogers-Graham K., Der C.J. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 2002, 277:9790-9799.
16. Prasad P.D., Stanton J.A., Assinder S.J. Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer. Cell Tissue Res 2010, 339:337-347.
17. Xie X.L., Liu Y.B., Liu Y.P., Du B.L., Li Y., Han M., et al. Reduced expression of SM22 is correlated with low autophagy activity in human colorectal cancer. Pathol Res Pract 2013, 209:237-243.
18. Feil S., Hofmann F., Feil R. SM22alpha modulates vascular smooth muscle cell phenotype during atherogenesis. Circ Res 2004, 94:863-865.
19. Shen J., Yang M., Ju D., Jiang H., Zheng J.P., Xu Z., et al. Disruption of SM22 promotes inflammation after artery injury via nuclear factor kappaB activation. Circ Res 2010, 106:1351-1362.
20. Shen J., Yang M., Jiang H., Ju D., Zheng J.P., Xu Z., et al. Arterial injury promotes medial chondrogenesis in Sm22 knockout mice. Cardiovasc Res 2011, 90:28-37.
21. Dong L.H., Wen J.K., Liu G., McNutt M.A., Miao S.B., Gao R., et al. Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia. Arterioscler Thromb Vasc Biol 2010, 30:683-691.
22. Lv P., Miao S.B., Shu Y.N., Dong L.H., Liu G., Xie X.L., et al. Phosphorylation of smooth muscle 22alpha facilitates angiotensin II-induced ROS production via activation of the PKCdelta-P47phox axis through release of PKCdelta and actin dynamics and is associated with hypertrophy and hyperplasia of vascular smooth muscle cells in vitro and in vivo. Circ Res 2012, 111:697-707.
23. Trapnell C., Pachter L., Salzberg S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25:1105-1111.
24. Trapnell C., Williams B.A., Pertea G., Mortazavi A., Kwan G., van Baren M.J., et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010, 28:511-515.
25. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
26. Huang da W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37:1-13.
27. Mi H., Muruganujan A., Thomas P.D. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013, 41:D377-D386.
28. Nam D., Ni C.W., Rezvan A., Suo J., Budzyn K., Llanos A., et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am J Physiol Heart Circ Physiol 2009, 297:H1535-H1543.
29. Jie W., Wang X., Zhang Y., Guo J., Kuang D., Zhu P., et al. SDF-1alpha/CXCR4 axis is involved in glucose-potentiated proliferation and chemotaxis in rat vascular smooth muscle cells. Int J Exp Pathol 2010, 91:436-444.
30. Kodali R.B., Kim W.J., Galaria I.I., Miller C., Schecter A.D., Lira S.A., et al. CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2004, 24:1211-1216.
31. Zhan M., Yuan F., Liu H., Chen H., Qiu X., Fang W. Inhibition of proliferation and apoptosis of vascular smooth muscle cells by ghrelin. Acta Biochim Biophys Sin (Shanghai) 2008, 40:769-776.
32. Tan H.W., Liu X., Bi X.P., Xing S.S., Li L., Gong H.P., et al. IL-18 overexpression promotes vascular inflammation and remodeling in a rat model of metabolic syndrome. Atherosclerosis 2010, 208:350-357.
33. Kanters E., Pasparakis M., Gijbels M.J., Vergouwe M.N., Partouns-Hendriks I., Fijneman R.J., et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003, 112:1176-1185.
34. Diez D., Wheelock A.M., Goto S., Haeggstrom J.Z., Paulsson-Berne G., Hansson G.K., et al. The use of network analyses for elucidating mechanisms in cardiovascular disease. Mol Biosyst 2010, 6:289-304.
35. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001, 12:297-304.
36. Westerterp M., Berbee J.F., Pires N.M., van Mierlo G.J., Kleemann R., Romijn J.A., et al. Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 2007, 116:2173-2181.
37. Dumont L., Gautier T., de Barros J.P., Laplanche H., Blache D., Ducoroy P., et al. Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI. J Biol Chem 2005, 280:38108-38116.
38. Nagelkerken L., Verzaal P., Lagerweij T., Persoon-Deen C., Berbee J.F., Prens E.P., et al. Development of atopic dermatitis in mice transgenic for human apolipoprotein C1. J Invest Dermatol 2008, 128:1165-1172.
39. Berbee J.F., van der Hoogt C.C., Sundararaman D., Havekes L.M., Rensen P.C. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 2005, 46:297-306.
40. Joh J.H.E.H., Kim D.I. Expression of apoC1 and FTL genes in human with carotid atherosclerosis. J Korean Surg Soc 2006, 1:56-60.
41. Chang C.T., Liao H.Y., Chang C.M., Chen C.Y., Chen C.H., Yang C.Y., et al. Oxidized ApoC1 on MALDI-TOF and glycated-ApoA1 band on gradient gel as potential diagnostic tools for atherosclerotic vascular disease. Clin Chim Acta 2013, 420:69-75.
42. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
43. van Diepen J.A., Berbee J.F., Havekes L.M., Rensen P.C. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 2013, 228:306-315.
44. McKellar G.E., McCarey D.W., Sattar N., McInnes I.B. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 2009, 6:410-417.
45. Zhang Y., Yang X., Bian F., Wu P., Xing S., Xu G., et al. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ. J Mol Cell Cardiol 2014, 72:85-94.
46. Zhang L., Peppel K., Sivashanmugam P., Orman E.S., Brian L., Exum S.T., et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:1087-1094.
47. Elhage R., Jawien J., Rudling M., Ljunggren H.G., Takeda K., Akira S., et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003, 59:234-240.
48. Mead J.R., Ramji D.P. The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovasc Res 2002, 55:261-269.
49. Warden C.H., Daluiski A., Bu X., Purcell-Huynh D.A., De Meester C., Shieh B.H., et al. Evidence for linkage of the apolipoprotein A-II locus to plasma apolipoprotein A-II and free fatty acid levels in mice and humans. Proc Natl Acad Sci U S A 1993, 90:10886-10890.
50. Yamauchi T., Kamon J., Waki H., Imai Y., Shimozawa N., Hioki K., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
51. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009, 1:a001651.
52. Hall G., Hasday J.D., Rogers T.B. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 2006, 41:580-591.
53. Calkin A.C., Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:1513-1518.
54. Dave V.P., Kaul D., Sharma Y., Bhattacharya R. Functional genomics of blood cellular LXR-alpha gene in human coronary heart disease. J Mol Cell Cardiol 2009, 46:536-544.
55. Thompson O., Moghraby J.S., Ayscough K.R., Winder S.J. Depletion of the actin bundling protein SM22/transgelin increases actin dynamics and enhances the tumourigenic phenotypes of cells. BMC Cell Biol 2012, 13:1.
56. Gerthoffer W.T. Mechanisms of vascular smooth muscle cell migration. Circ Res 2007, 100:607-621.
57. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007, 117:568-575.
58. Bowers S.L., Banerjee I., Baudino T.A. The extracellular matrix: at the center of it all. J Mol Cell Cardiol 2010, 48:474-482.
59. Blankenberg S., Barbaux S., Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003, 170:191-203.
60. Katsuda S., Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003, 10:267-274.
61. Ley K., Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest 2001, 107:1209-1210.
62. Nakashima Y., Raines E.W., Plump A.S., Breslow J.L., Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998, 18:842-851.
63. Caird J., Napoli C., Taggart C., Farrell M., Bouchier-Hayes D. Matrix metalloproteinases 2 and 9 in human atherosclerotic and non-atherosclerotic cerebral aneurysms. Eur J Neurol 2006, 13:1098-1105.
64. Yaghini F.A., Song C.Y., Lavrentyev E.N., Ghafoor H.U., Fang X.R., Estes A.M., et al. Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation. Hypertension 2010, 55:1461-1467.
65. Clempus R.E., Griendling K.K. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res 2006, 71:216-225.
66. Deng Y., Theken K.N., Lee C.R. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 2010, 48:331-341.